Deborah Lindquist

5.4k citations

22 papers · 3.0k indexed · 1 hit paper · h-index 10

Oncology top 1%
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 11
- Lung Cancer Research Studies 3
Cancer Research top 2%
- Breast Cancer Treatment Studies 7
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research 3
Genetics top 5%
Pulmonary and Respiratory Medicine top 2%
- Advanced Breast Cancer Therapies 7
- Lung Cancer Treatments and Mutations 4
Dermatology
- Chemotherapy-related skin toxicity 3

Co-authors: David Cameron Charles E. Geyer Steven Stein Mario Campone Agnieszka Jagiełło-Gruszfeld Cristina Oliva John Crown Stephen Chan
Cited by: Oncology Cancer Research Radiology, Nuclear Medicine and Imaging
Journals: Journal of Clinical Oncology (6 papers)Cancer Research (3 papers)Lung Cancer (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Deborah Lindquist

22 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Deborah Lindquist

Since Specialization

Citations

This map shows the geographic impact of Deborah Lindquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Lindquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Lindquist more than expected).

Fields of papers citing papers by Deborah Lindquist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Lindquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Lindquist. The network helps show where Deborah Lindquist may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Deborah Lindquist, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deborah Lindquist Line = papers co-authored together Deborah Lindquist links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients npj Breast Cancer ·Devchand Paul,Svetislava J. Vukelja,Frankie A. Holmes,Joanne L. Blum,Kristi McIntyre,Deborah Lindquist,Cynthia R. Osborne,Heike Thiel,Jerome H. Goldschmidt,Yunfei Wang,Lina Asmar,Lewis C. Strauss,Joyce O’Shaughnessy	2019	11
2	Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease Case Reports in Oncology ·K. E. Grund,Deborah Lindquist	2018	4
3	Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib Clinical Lung Cancer ·Flemming Dahl,Justin M. Honce,Deborah Lindquist,D. Ross Camidge	2018	6
4	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial Breast Cancer Research and Treatment ·Joyce O’Shaughnessy,Katarína Petráková,Gabe S. Sonke,Pierfranco Conté,Carlos L. Arteaga,David Cameron,Lowell L. Hart,Cristian Villanueva,Erik Jakobsen,J. Thaddeus Beck,Deborah Lindquist,Farida Souami,S. Mondal,Caroline Germa,Gabriel N. Hortobágyi	2017	87
5	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy European Journal of Cancer ·Kathrin Strasser‐Weippl,Nora Horick,Ian E. Smith,Joyce O’Shaughnessy,Bent Ejlertsen,Frances Boyle,Aman U. Buzdar,P. Fumoleau,William J. Gradishar,Miguel Martín,Beverly Moy,Martine Piccart,Kathleen I. Pritchard,Deborah Lindquist,Erica Rappold,Dianne M. Finkelstein,Paul E. Goss	2016	4
6	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy Breast Cancer Research ·Kathrin Strasser‐Weippl,Nora Horick,Ian E. Smith,Joyce O’Shaughnessy,Bent Ejlertsen,Frances Boyle,Aman U. Buzdar,P. Fumoleau,William J. Gradishar,Miguel Martín,Beverly Moy,Martine Piccart,Kathleen I. Pritchard,Deborah Lindquist,Erica Rappold,Dianne M. Finkelstein,Paul E. Goss	2015	26
7	Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study The Lancet Oncology ·Bog-Cheon Choi,Marko Baretić,Devchand Paul,Scot Sedlacek,Anne Favret,Ira Gore,Deborah Lindquist,Frankie A. Holmes,Mary Ann Allison,Shellen Halim,Baharak Partowazar,Svetislava J. Vukelja,Michael S. Steinberg,Christopher Stokoe,S. V. Mihovski,Yunfei Wang,Lina Asmar,Nicholas J. Robert,Joyce O’Shaughnessy	2013	92
8	Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy Breast Cancer Research and Treatment ·Linda T. Vahdat,Agustin A. García,Charles L. Vogel,Christine Pellegrino,Deborah Lindquist,Nicholas Iannotti,Prashanth Gopalakrishna,Joseph A. Sparano	2013	46
9	ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology ·Joyce O’Shaughnessy,David Loesch,Devchand Paul,Christopher Stokoe,John Pippen,Joanne L. Blum,Malek A. Alsulami,Frankie A. Holmes,Svetislava J. Vukelja,Deborah Lindquist,John F. Sandbach,Scot Sedlacek,Yunfei Wang,Stephen E. Jones	2013	1
10	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial The Lancet Oncology ·Paul E. Goss,Ian E. Smith,Joyce O’Shaughnessy,Bent Ejlertsen,Manfred Kaufmann,Frances Boyle,Aman U. Buzdar,P. Fumoleau,William J. Gradishar,Miguel Martín,Beverly Moy,Martine Piccart,Kathleen I. Pritchard,Deborah Lindquist,Yanin Chávarri-Guerra,Gursel Aktan,Erica Rappold,Lisa S. Williams,Dianne M. Finkelstein	2012	100
11	Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study Annals of Oncology ·Marko Baretić,P. Pakhlov,José Augusto Alves Moreira,Timothy George,Stefan Krüger,Anne Favret,Deborah Lindquist,A. Melnyk,李清良,Spencer H. Shao,S. V. Mihovski,Lina Asmar,J. O’Shaughnessy	2012	6
12	Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study. Journal of Clinical Oncology ·Linda T. Vahdat,Agustin A. García,Charles L. Vogel,Christine Pellegrino,Deborah Lindquist,Joseph A. Sparano,Prashanth Gopalakrishna,Nicholas Iannotti	2012	1
13	Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology ·Joyce O’Shaughnessy,John Pippen,Devchand Paul,Christopher Stokoe,Joanne L. Blum,Malek A. Alsulami,Frankie A. Holmes,Andreas Wosol,Svetislava J. Vukelja,Deborah Lindquist,Scot Sedlacek,Ragene Rivera,Robert J. Brooks,Kristi McIntyre,Yunfei Wang	2012	3
14	Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses. Journal of Clinical Oncology ·John Pippen,Devchand Paul,Christopher Stokoe,Joanne L. Blum,Malek A. Alsulami,F. Sobela,Deborah Lindquist,Scot Sedlacek,Ragene Rivera,Robert J. Brooks,S. Vukelja,Kristi McIntyre,Andreas Wosol,J. O’Shaughnessy	2011	9
15	P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study. Cancer Research ·Linda T. Vahdat,P. Gopalakrishna,R. Farina,Charles L. Vogel,C. Pellegrino,Deborah Lindquist,Nicholas Iannotti	2011	1
16	Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer Journal of Clinical Oncology ·David Loesch,F. Anthony Greco,Neil Senzer,Howard A. Burris,John D. Hainsworth,Stephen E. Jones,Svetislava J. Vukelja,John F. Sandbach,Frankie A. Holmes,Scot Sedlacek,John Pippen,Deborah Lindquist,Kristi McIntyre,Joanne L. Blum,Manuel Modiano,Kristi A. Boehm,Feng Zhan,Lina Asmar,Nicholas J. Robert	2010	17
17	Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer Cancer Research ·Joyce O’Shaughnessy,Audrey Lebois,Christopher Stokoe,John Pippen,JL Blum,Malek A. Alsulami,Daniel Mill,Svetislava J. Vukelja,Deborah Lindquist,Scot Sedlacek,Ragene Rivera,Robert J. Brooks,Kristi McIntyre,李清良,Jonathan Schwartz,Sharon Jones,Carrie Brownstein,Frank Gilberg	2010	29
18	Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancerbreakdown → New England Journal of Medicine ·Charles E. Geyer,A. Chiba,Deborah Lindquist,Stephen Chan,S. I. Mironov,Tadeusz Pieńkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,Steven Stein,David Cameron	2006	2498
19	Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2 Lung Cancer ·Matilde Heydorn Koopmann,John F. Sandbach,Ann B. Sumner,T. Awzoglu,Deborah Lindquist,Paul Conkling,D. Ilegbodu,Lina Asmar	2006	2
20	Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer Lung Cancer ·Marcus A. Neubauer,David Garfield,Xiaoli Zhang,Robert N. Raju,Deborah Lindquist,艳惜,Myrna M. Khan,Kristi A. Boehm,Lina Asmar	2004	15

About Deborah Lindquist

Deborah Lindquist is a scholar working on Oncology, Cancer Research, Dermatology, Pulmonary and Respiratory Medicine and Genetics, having authored 22 papers that have together received 3.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Cancer Treatment and Pharmacology (11 papers), Advanced Breast Cancer Therapies (7 papers), Breast Cancer Treatment Studies (7 papers), Lung Cancer Treatments and Mutations (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Lung Cancer Research Studies (3 papers) and Chemotherapy-related skin toxicity (3 papers). The work is most often cited by research in Oncology (2.5k citations), Cancer Research (648 citations), Radiology, Nuclear Medicine and Imaging (812 citations), Genetics (316 citations) and Pulmonary and Respiratory Medicine (938 citations). Deborah Lindquist has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include David Cameron, Charles E. Geyer, Steven Stein, Mario Campone, Agnieszka Jagiełło-Gruszfeld, Cristina Oliva, John Crown, Stephen Chan, Stephen D. Rubin and Bella Kaufman. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Lung Cancer, The Lancet Oncology and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact